👋 Hey, let’s get into it. Three deaths on a cruise ship. A rare virus in global headlines. And biotech stocks immediately started moving like it was 2020 again.

Moderna surged after reports tied the company to early stage hantavirus vaccine research, reminding everyone that markets can turn any health scare into a trading thesis before lunch.

Officials say public risk remains low and broader spread is unlikely, but traders saw “outbreak,” “vaccine,” and “mRNA” in the same sentence and reached for the buy button without a second thought.

We go deeper on the hantavirus story in today’s Deep Dive.

🚪 Trump Eyes the Exit for FDA Chief Marty Makary
President Donald Trump is reportedly preparing to remove FDA Commissioner Marty Makary, though sources say the decision is not yet final. Makary’s 14-month tenure has been marked by layoffs, leadership turnover, and criticism from both industry and political camps. Recent flashpoints include hesitation around flavored vaping products, inconsistent drug review timelines, and accusations that politics has seeped into scientific decision-making. Hundreds of industry leaders previously urged the agency to restore predictability. If Makary goes, the FDA may be headed for yet another reset before it finds stable footing.

📉 CSL’s $5B Reality Check Hits Hard
Australia’s CSL slashed its full-year revenue forecast from $15.8 billion to $15.2 billion and announced a $5 billion impairment charge tied largely to underperforming assets from its 2022 Vifor Pharma acquisition. Shares plunged roughly 16%, extending a brutal year that has already seen the stock fall more than 40%. Interim leadership blamed late-stage R&D misses, market-share erosion, and excess immunoglobulin inventory in the U.S. channel. It would mark CSL’s first annual revenue decline in more than a decade.

🤑 Gilead Sees $1B Future for Yeztugo After Breakout Launch
Gilead raised its first-year sales forecast for long-acting HIV prevention drug Yeztugo to $1 billion after an opening quarter that brought in $166 million. Executives called the launch trajectory unprecedented, with demand coming both from patients switching off older PrEP options and first-time users entering prevention care. The performance adds momentum to Gilead’s already dominant HIV franchise, which generated $5 billion in quarterly revenue. For a company long defined by treatment, prevention is suddenly becoming another growth engine.

🇮🇹 Angelini Pays $4.1B to Buy Catalyst and Enter Rare Disease
Italy’s Angelini Pharma agreed to acquire Catalyst Pharmaceuticals for $4.1 billion, giving the family-owned drugmaker a much larger foothold in the lucrative U.S. market. The deal hands Angelini control of Firdapse, Catalyst’s neuromuscular disorder drug, plus a business that posted $589 million in 2025 sales. Catalyst shareholders receive $31.50 per share. Angelini just skipped the slow build and bought scale outright.

🏭 Daiichi’s ADC Expansion Turns Into a $610M Costly Overshoot
Daiichi Sankyo warned profits will take a $610 million hit after overestimating future demand for its antibody-drug conjugate portfolio. Earlier blockbuster expectations for Enhertu and related assets pushed the company into long-term manufacturing commitments and planned plant expansion. But shifting trial timelines, evolving patient populations, and softer forecasts forced Daiichi to compensate contract manufacturers and cancel internal buildouts. Being too optimistic can get very expensive very quickly.

🤖 Roche Buys PathAI for Up to $1.05B
Roche will pay $750 million upfront to add PathAI’s digital pathology tools and expand precision cancer diagnostics.

📉 Sarepta Slips Despite Revenue Beat
Elevidys topped forecasts but declining quarterly sales and pipeline uncertainty pushed Sarepta shares down more than 10%.

✅ Partner Wins Fast FDA Nod
Bizengri gained approval for ultra-rare cholangiocarcinoma days after receiving the agency’s new priority voucher designation.

💥 Entrada Stock Gets Crushed
Weak Duchenne data missed expectations badly sending shares down 59% and boosting rival exon-skipping programs.

💸 Odyssey Prices $304M IPO
Odyssey upsized its offering, priced shares at the top of its range, and debuted on Nasdaq as ODTX.

💊 Blackstone Backs Anagram With $250M
Funding will advance a three-pill enzyme therapy aiming to replace burdensome 40-pill daily regimens today.

😳 Capricor Sues Its U.S. Partner
Capricor claims NS Pharma failed launch preparations for deramiocel ahead of a key FDA decision date.

Three deaths. Multiple confirmed infections. A quarantined expedition cruise ship. If that sounds like the trailer for a streaming thriller, unfortunately, it’s real life.

A hantavirus outbreak tied to the MV Hondius cruise ship has pushed an obscure pathogen into global headlines. The strain involved is Andes virus, notable because it is the only hantavirus known to occasionally spread person to person. With the Covid pandemic still in the back of people’s minds, public health officials keep emphasizing that the broader risk is low.

There is currently no approved cure or vaccine for hantavirus. That’s where biotech enters the story. Moderna confirmed it has conducted preclinical hantavirus research with the U.S. Army and also partnered with Korea University on early vaccine work. Other vaccine names like Novavax, Inovio, and Emergent got sympathy trade attention as investors looked for “the next outbreak play.” On a side note, biotech and pharma investors might be the only group of people who view the COVID pandemic as the “good ol’ days.”

The more interesting story is what isn’t ready. Researchers previously developed an antibody that protected hamsters from Andes virus infection, with hopes it could be used after exposure or early in illness. Unfortunately, funding expired before human trials could begin.

This is the recurring outbreak cycle. A rare disease simmers quietly for years, funding dries up, then a cluster appears and capital markets rediscover it overnight. Hantavirus vaccines and treatments may not become commercial blockbusters, as revenue potential is limited. But the bigger lesson here is not just about one virus. It’s that markets reward preparedness only after danger appears. Science asks for funding early, but panic prefers to pay later.

That’s how many biotech and pharma layoff rounds were announced this year by the end of April. Hopes for a calmer 2026 job market are fading as pipeline failures, restructurings, and cost pressure continue to hit payrolls.

Here’s what biotech Redditors are talking about:

🙄 “Great news, we’re expanding... somewhere else.”
A Reddit thread erupted after users noticed more pharma and biotech openings shifting to India while U.S. and European postings shrink. Frustration centered less on global hiring itself and more on seeing local cuts marketed as corporate growth stories. Several commenters argued companies underestimate time-zone friction and turnover abroad before eventually rebalancing. Nothing boosts morale like your replacement being labeled strategic efficiency.

🎓 “Just go to med school” is terrible casual advice
Another thread roasted the common suggestion that struggling biotech grads should simply pivot into medicine. Users pointed to massive debt loads, brutal training timelines, residency stress, and the fact that enjoying biology does not equal wanting to treat patients daily. Others noted medicine and biotech require very different personalities and career motivations… Liking airplanes does not mean you should become a pilot.

🤖 AI Beats ER Doctors
A Harvard study found AI outperformed physicians in emergency triage diagnoses, scoring 67% accuracy versus 50%-55% for human doctors in rapid test scenarios.

🦠 Measles Gets New Enemies
Researchers identified antibodies from vaccinated donors that blocked measles infection in animal models after exposure and before symptoms.

🧠 Liver-to-Brain Workaround
A gene therapy delivered to the liver reduced amyloid plaques and improved cognition in mice during testing.

🌳 Banyan BioInnovations Wants to Grow Startups
Banyan BioInnovations launched with more than $100 million to create independent companies around promising clinical-stage assets. Instead of betting everything on one pipeline, Banyan plans a portfolio model with shared infrastructure, centralized operators, and trial support through partner Icon. The firm says one program’s failure should not sink the whole platform. Their metaphor is…drum roll please…the banyan tree: multiple trunks, broad canopy, resilient structure.

🕯️ May 12, 1820 — Florence Nightingale is Born
Florence Nightingale, also known as “The Lady with the Lamp,” was born today in Florence, Italy, and went on to transform modern nursing, hospital hygiene, and healthcare analytics. During the Crimean War, she helped slash death rates through sanitation reforms and disciplined patient care. She also used charts and statistical visuals to persuade policymakers long before dashboards became executive wallpaper. International Nurses Day is celebrated on her birthday for good reason.

Public health officials keep ending every hantavirus update with “don’t panic,” which historically feels like shouting “stay calm” into a crowded theater. Markets already ignored that advice, traders hit buy, and Moderna got another reminder that fear can be bullish.

See you Thursday for the next issue, ideally from a land-based location. 👋

If you’re enjoying BioNucleus, share it with a friend or coworker who’d get value from it. We’re a small operation, and every share makes a bigger difference than you think.

Was this email forwarded to you? Sign up here 👇

Subscribe for free

Follow us on social and stay one step ahead